It was demonstrated that transgenic introduction of human sclerostin gene (SOST) and exposure to recombinant mice sclerostin in mice with ApoE−/− deficiency slowed down the formation of atherosclerosis and Ang II-induced AAA. This evidence concerns the gene SOST and triple-A syndrome.